BioCryst Pharmaceuticals (BCRX) said Friday that Colombia's National Institute of Drug and Food Surveillance has approved Orladeyo to prevent hereditary angioedema attacks in patients at least 12 years old.
The company said it has an exclusive collaboration with Pint Pharma for Orladeyo in the pan-Latin America region, with Pint in charge of all marketing authorizations and commercialization in the region.
Orladeyo has also been approved in Chile, Argentina, Brazil, Mexico and Peru, the company said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。